Chronic Distress Post-MI Increases Risk for Death
Heart attack survivors with persistent emotional distress — depression or anxiety — are at a higher risk for death.
Myocardial Infarction
Consensus Statement on Genetic Testing for Guiding Post-PCI Antiplatelet Therapy
International expert panel provides consensus statements on the use of platelet function and genetic testing for guiding antiplatelet treatment after percutaneous coronary intervention.
Feelings of Powerlessness Tied to Delays in Seeking Care for Acute MI
Patients’ perceived inability to act is associated with a delay in seeking medical care for acute myocardial infarction.
More Aggressive Statin Therapy Needed Post-MI in Young Patients
Majority of patients with heart attack <50 years still have high cholesterol one year later
Undetected Dysglycemia Linked to Myocardial Infarction
Undetected dysglycemia is associated with both myocardial infarction and periodontitis.
Drug-Coated Balloon Angioplasty Noninferior to Drug-Eluting Stent for STEMI
Drug-coated balloon angioplasty may allow for the restoration of normal coronary physiology and enable positive vessel remodeling.
Familial Hypercholesterolemia Needs Aggressive Lipid-Lowering Therapy After MI
Researchers assessed the incidence of clinically defined familial hypercholesterolemia and analyzed the rates of statin use and low-density lipoprotein cholesterol 1 year after myocardial infarction.
Unrecognized MI Is Common, Increases Mortality Risk in Asymptomatic Patients With Diabetes
Researchers conducted a prospective study focusing on asymptomatic patients with diabetes to investigate the prevalence and prognostic significance of unrecognized MI.
Alirocumab Approved by FDA to Reduce Serious Cardiovascular Event Risk
The FDA has approved Praluent (alirocumab; Sanofi and Regeneron), a PCSK9 inhibitor, to reduce the risk of myocardial infarction (MI), stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease.
Final Infarct Size Similar With Complete vs Culprit Lesion PCI in STEMI
Complete fractional flow reserve-guided revascularization in patients with STEMI and multivessel disease did not affect final infarct size, LV function, or remodeling compared with culprit-only percutaneous coronary intervention.
